The Medical Letter on Drugs and Therapeutics
August 27, 2018
Management of Opioid Withdrawal Symptoms
|Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.|
Management of Opioid Withdrawal Symptoms
August 27, 2018 (Issue: 1554)Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent...more
- The American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. June 1, 2015. Available at: www. asam.org. Accessed August 9, 2018.
- MA Schuckit. Treatment of opioid-use disorders. N Engl J Med 2016; 375:357.
- British Columbia Ministry of Health. A guideline for the clinical management of opioid use disorder. June 5, 2017. Available at: https://www2.gov.bc.ca.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- Opioids for pain. Med Lett Drugs Ther 2018; 60:57.
- H Hassanian-Moghaddam et al. Withdrawal syndrome caused by naltrexone in opioid abusers. Hum Exp Toxicol 2014; 33:561.
- Substance Abuse and Mental Health Services Administration. Buprenorphine waiver management. January 18, 2018. Available at: www.samhsa.gov. Accessed August 9, 2018.
- Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.
- In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther 2013; 55:83.
- Bunavail: another buprenorphine/naloxone formulation for opioid dependence. Med Lett Drugs Ther 2015; 57:19.
- L Gowing et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2017; 2:CD002025.
- DP Kao et al. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction 2015; 110:1468.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed August 9, 2018.
- Institute for Safe Medication Practices. Keeping patients safe from iatrogenic methadone overdoses. February 14, 2008. Available at: www.ismp.org. Accessed August 9, 2018.
- Substance Abuse and Mental Health Services Administration. Emerging issues in the use of methadone. Substance abuse treatment advisory: news for the treatment field. Spring 2009; 8:1. Available at: https://store.samhsa.gov. Accessed August 9, 2018.
- L Gowing et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2016; 5:CD002024.
- RL Woosley and KA Romero. QT drugs list. Available at: www. crediblemeds.org. Accessed August 9, 2018.
- NM Wright et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. Br J Gen Pract 2011; 61:e772.
- U.S. Government Publishing Office. 42 CFR 8.12 – Federal opioid treatment standards. Available at: www.gpo.gov. Accessed August 9, 2018.
- Lofexidine (Lucemyra) for opioid withdrawal. Med Lett Drugs Ther 2018; 60:115.
- CW Gorodetzky et al. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend 2017; 176:79.
- W Ling et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090.
- L Amato et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011; 9:CD005031.
- L Gowing et al. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2017; 5:CD002021.
- American Society of Addiction Medicine. Public policy statement on rapid and ultra rapid opioid detoxification. 2005. Available at: www.asam.org. Accessed August 9, 2018.
- SC Sigmon et al. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse 2012; 38:187.
- CDC. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification – New York City, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:777.
- ACOG Committee on Health Care for Underserved Women and American Society of Addiction Medicine. ACOG committee opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070.
- KA Saia et al. Caring for pregnant women with opioid use disorder in the USA: expanding and improving treatment. Curr Obstet Gynecol Rep 2016; 5:257.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.